Intra-articular haemorrhage caused by reduced recovery of PEGylated recombinant factor VIII due to an anti-PEG antibody developed after mRNA-1273 SARS-CoV-2 vaccination in haemophilia A

Haemophilia. 2023 May;29(3):935-938. doi: 10.1111/hae.14786. Epub 2023 Apr 11.

Authors

Yuto Nakajima^{1

2}, Kenichi Ogiwara¹, Naruto Shimonishi^{1

3}, Shoko Furukawa¹, Masahiro Takeyama¹, Keiji Nogami¹

Affiliations

¹ Department of Paediatrics, Nara Medical University, Kashihara, Nara, Japan.
² Advanced Medical Science of Thrombosis and Haemostasis, Nara Medical University, Kashihara, Nara, Japan.
³ The Course of Thrombosis and Haemostasis Molecular Pathology, Nara Medical University, Kashihara, Nara, Japan.

PMID: 37040322
DOI: 10.1111/hae.14786

No abstract available

Publication types

Case Reports
Letter
Comment

MeSH terms

2019-nCoV Vaccine mRNA-1273
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Factor VIII / therapeutic use
Hemophilia A* / drug therapy
Hemorrhage* / etiology
Humans
Polyethylene Glycols
SARS-CoV-2
Vaccination

Substances

2019-nCoV Vaccine mRNA-1273
COVID-19 Vaccines
Factor VIII
Polyethylene Glycols